This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

PHA-739358 for the Treatment of Multiple Myeloma

This study has been terminated.
(Low recruitment rate)
Information provided by (Responsible Party):
Nerviano Medical Sciences Identifier:
First received: March 30, 2009
Last updated: May 13, 2014
Last verified: May 2014
The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.

Condition Intervention Phase
Multiple Myeloma Drug: PHA-739358 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: An Exploratory Phase II Study of PHA-739358 in Patients With Multiple Myeloma Harbouring the t(4;14) Translocation With or Without FGFR3 Expression

Resource links provided by NLM:

Further study details as provided by Nerviano Medical Sciences:

Primary Outcome Measures:
  • Response Rate according to International Myeloma Working Group uniform response criteria for multiple myeloma. [ Time Frame: At end of each cycle ]

Secondary Outcome Measures:
  • Overall safety profile [ Time Frame: All cycles ]

Enrollment: 7
Study Start Date: October 2008
Study Completion Date: September 2010
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: PHA-739358
Weekly IV infusion for 3 consecutive weeks in a 4-week cycle


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • active multiple myeloma progressing after at least 2 prior lines of treatment
  • measurable disease
  • t(4;14) translocation
  • life expectancy of at least 3 months

Exclusion Criteria:

  • uncontrolled hypertension
  • myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the past 6 months.
  • pregnancy or breast feeding
  • active infections, including HIV
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00872300

United States, Arizona
MAYO Clinic
Scottsdale, Arizona, United States, 85259
United States, Illinois
The Robert H Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States, 60611
Hôpital Huriez, Centre Hospitalier Régional Universitaire de Lille
Lille, France, 59037
University Hospital Hôtel-Dieu
Nantes, France, 44093
Sponsors and Collaborators
Nerviano Medical Sciences
  More Information

Responsible Party: Nerviano Medical Sciences Identifier: NCT00872300     History of Changes
Other Study ID Numbers: AURA-6202-011
Study First Received: March 30, 2009
Last Updated: May 13, 2014

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases processed this record on June 23, 2017